Browse the evidence

Short-term increases in energy intake and body weight observed in ultra-processed food (UPF) feeding trials are primarily mediated by higher energy density rather than the processing status itself, and these effects attenuate over time.

Do not demonize ultra-processed foods (UPF) based solely on their processing status. The observed weight gain in short-term studies is largely driven by high energy density, which tends to decrease as the body adapts. If you choose to eat UPF, ensure they are matched for energy density and nutrient quality with less processed options, as no inherent adverse effect on energy intake was found in controlled trials using conservative substitutions.

Among US women, younger age, Black race, lower income, less than 12 years of education, obesity (BMI ≥ 30), and current smoking are significantly associated with reporting both poor diet and low physical activity.

Public health initiatives targeting diet and physical activity should prioritize younger women, Black women, those with lower income and education levels, and current smokers, as these groups show the highest prevalence of combined poor diet and inactivity. Interventions should address socioeconomic barriers rather than assuming uniform access to resources.

Membership in commercial Nutrition Clubs providing fortified meal replacements and nutrition education is associated with significantly lower fasting insulin, lower HbA1c, higher vitamin D and vitamin E status, and a lower prevalence of metabolic syndrome compared to community-matched controls.

Joining a structured nutrition program that uses meal replacements and provides education can significantly improve metabolic health markers like insulin sensitivity and vitamin levels, even if weight loss isn't the primary visible outcome. The key is consistency (weekly attendance) and the nutritional quality of the replacements.

Individuals with high obesity genetic risk scores (GRS) experience greater initial weight loss during the first 6 months of behavioral interventions but are significantly more susceptible to weight regain during the subsequent 6 months compared to those with low GRS.

If you have a strong family history of obesity, expect to lose weight quickly when you start a diet, but be vigilant about maintenance. Your body may fight back harder to regain weight after the initial loss. Focus heavily on the strategies that help you maintain weight loss after the first 6 months, as this is where your genetic risk profile shows a tendency for regain.

Chronic administration of the GLP-1/GIP dual agonist I-M-150847 significantly improves glycemic control and reduces body weight and adiposity in diet-induced obese rodents compared to the GLP-1 monoagonist exendin-4.

This preclinical study suggests that a novel dual GLP-1/GIP agonist (I-M-150847) may provide better blood sugar control and weight loss than current GLP-1-only drugs in obese individuals with type 2 diabetes. While promising in mice, human clinical data is required before this can be recommended for clinical use.

Carbohydrate-restricted nutrition therapy (CRNT) supported by continuous remote care enables the deprescription of GLP-1 receptor agonists in people with type 2 diabetes without regression of glycemic control or body weight loss.

If you are on a GLP-1 drug (like Ozempic or Wegovy) for Type 2 Diabetes or weight, you do not necessarily have to take it forever. This study suggests that if you adopt a medically-supervised ketogenic diet (low carb, high healthy fat) and monitor your blood ketones, you may be able to stop the drug while keeping your weight and blood sugar stable. The key is that the diet reduces hunger hormones, doing the job the drug was doing, allowing you to step off the medication without regaining weight.

Caloric restriction through structured dietary interventions improves functional capacity and quality of life in patients with HFpEF.

For HFpEF patients, structured caloric restriction programs that provide all meals can lead to significant weight loss and improved heart function. This approach is supported by guidelines and can be a viable alternative or adjunct to medication.

Combination pharmacotherapy for obesity is significantly more effective than monotherapy.

If one weight loss medication isn't working well, ask your doctor about combination therapies. They combine two drugs to target different pathways, often resulting in greater weight loss than a single drug.

Patients with Type 2 Diabetes Mellitus (T2DM) experience greater cardiovascular benefits and fewer adverse events from Tirzepatide compared to patients with obesity alone.

If you have both T2DM and obesity, or just T2DM, you may get more cardiovascular benefits and fewer side effects from Tirzepatide than if you have obesity alone. This suggests that your specific health condition plays a role in how well the medication works for you. Discuss your specific health profile with your doctor to understand what to expect.

Patients prefer surgical weight loss over medical interventions, even when medical interventions offer similar weight loss, but are willing to use adjuvant AOMs post-surgery for additional loss.

Even if a medication could make you lose the same amount of weight as surgery, most patients still prefer surgery. This suggests that surgery offers benefits beyond just the number on the scale, such as durability or health improvements, which patients value highly.

A post-operative 'Difficulty to control eating' score of ≤7 at 3 months after sleeve gastrectomy independently predicts achieving ≥25% total weight loss at one year.

If you had sleeve gastrectomy, use a validated eating control questionnaire (like the CoEQ) around the 3-month mark. A low score on 'difficulty to control eating' (≤7) is a strong signal you will likely achieve significant weight loss (≥25%). If your score is high, seek early behavioral intervention to improve control, as this is a better predictor of success than how much you weighed in the first few weeks.

Energy intake goals for obesity treatment should be personalized, but general guidance based on sex is currently the standard in evidence-based guidelines.

While your calorie needs are unique, most official guidelines give general energy targets based on your sex, not your exact weight. This is the current standard in evidence-based recommendations for obesity treatment.

GLP-1 receptor agonist therapy initiated at least one year after bariatric surgery produces additional significant weight loss with a favorable safety profile.

If you had bariatric surgery and are struggling with weight regain, GLP-1 medications (like semaglutide or dulaglutide) can help you lose more weight safely. Start with a low dose and work up slowly to minimize stomach issues. Combining the medication with a structured lifestyle program (like the VA's MOVE!) yields the best results.

GLP-1 receptor agonists (GLP-1RAs) improve reproductive outcomes in obese women with PCOS or unexplained infertility by reducing body weight, improving insulin sensitivity, and modulating endometrial immune balance (increasing Treg cells, decreasing pro-inflammatory cytokines, and restoring Th17/Treg balance).

For women with obesity and fertility issues (like PCOS), GLP-1 medications can help restore ovulation and improve the uterine environment by lowering inflammation. However, these drugs must be stopped before you conceive because they can harm the developing embryo. The goal is to use them during the preconception phase to fix metabolic and immune imbalances, then switch to pregnancy-safe management once pregnant.

Semaglutide improves patient-reported pain and function in chronic plantar heel pain, with approximately half of the benefit mediated by weight loss.

If you have chronic heel pain and are overweight or have Type 2 Diabetes, ask your doctor if GLP-1 medications like semaglutide might help. The study suggests these drugs can reduce pain and improve foot function, largely by helping you lose weight, which reduces stress on your feet. This is not a standard treatment yet, so discuss the risks and benefits with your provider.

Metabolic and bariatric surgery (MBS) significantly improves self-esteem, body image, and health-related quality of life, with the greatest gains occurring within the first 12 months post-surgery.

Expect a significant boost in self-esteem and quality of life within the first year after surgery. Be prepared for a period where your external appearance changes faster than your internal self-image, which can cause temporary discomfort.

MBS leads to marked improvements in sexual function for both men and women, including increased libido, erectile function, and hormonal normalization, typically within the first 12 months.

Expect significant improvements in sexual function and hormonal health within the first year after surgery. These changes are driven by weight loss and hormonal recalibration. Address any performance anxiety through counseling to maximize benefits.

Family involvement and structured family therapy significantly enhance postoperative weight loss, adherence, and psychosocial outcomes.

Involve your family in your postoperative care. Structured family therapy can significantly improve weight loss and psychosocial outcomes. Address any family resistance through open communication and counseling.

GLP-1 receptor agonists (e.g., semaglutide) induce significant weight loss through hormonal mechanisms but carry a high risk of psychological dependency and rebound weight gain upon discontinuation, necessitating their use as temporary adjuncts to lifestyle interventions rather than standalone long-term solutions.

If you are using GLP-1 drugs, treat them as a temporary bridge to build sustainable habits, not a permanent solution. Prioritize resistance training and protein intake to protect muscle mass, as rapid weight loss without exercise increases frailty risk. Plan for discontinuation early by integrating behavioral therapy and dietary changes to prevent rebound weight gain and dependency.

Sirona, a gastro-retentive dual-network polymer hydrogel, promotes weight loss and reduces dietary intake in adults with obesity (BMI 30-40 kg/m2) through mechanical gastric retention, demonstrating a large effect size compared to placebo in a 12-week pilot trial.

Sirona is a non-drug weight loss option for people with obesity (BMI 30-40). It works by swelling in the stomach to help you feel full, leading to reduced food intake and weight loss. In a short trial, it helped people lose about 4% of their body weight over 12 weeks, which is a significant amount. Side effects like nausea are common at first but are usually mild and go away. It requires taking pills daily with water on an empty stomach, along with basic healthy eating and exercise advice.

Tirzepatide, a dual GLP-1/GIP receptor agonist, demonstrates significant efficacy in reducing body weight (over 20% in some cases) and improving glycemic control in patients with type 2 diabetes and obesity, suggesting therapeutic potential for women with Polycystic Ovary Syndrome (PCOS) who have comorbid obesity and insulin resistance.

For women with PCOS and obesity, tirzepatide offers a promising pharmacological tool to address both metabolic and reproductive symptoms. While not yet standard care for PCOS specifically, its ability to induce significant weight loss (>20%) and improve insulin sensitivity suggests it may help restore ovulation and reduce androgen levels. Treatment involves weekly subcutaneous injections starting at 2.5mg and titrating up to 15mg, ideally combined with lifestyle changes. Patients should be aware of potential GI side effects, though the drug's design aims to mitigate them.

GLP-1 agonists (semaglutide, tirzepatide) produce significant weight loss (15-21%) but are associated with isolated reports of depression and suicidal ideation, though causal links remain unproven.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss (15-21%), but require careful psychological monitoring. While serious mental health side effects are reported, they are isolated and not causally proven. You should undergo regular mental health check-ins alongside your medical treatment to ensure safety.

Naltrexone/Bupropion combination therapy offers good psychiatric tolerability with only mild, transient anxiety and insomnia, making it a safe alternative for patients concerned about mood stability.

Naltrexone/Bupropion is a well-tolerated weight loss option with a favorable psychiatric profile. While you may experience mild anxiety or insomnia initially, these do not typically progress to serious conditions. It is particularly suitable for patients with emotional eating patterns.

Using GLP-1 RAs post-bariatric surgery can enhance weight loss outcomes and prevent weight regain, whereas using them pre-surgery (neoadjuvant) does not improve surgical outcomes and may slightly reduce weight loss.

If you have had bariatric surgery and are experiencing weight regain, adding a GLP-1 RA can help you lose additional weight. However, taking GLP-1 RAs *before* surgery does not improve surgical results and might slightly reduce the amount of weight lost from the surgery itself.